Usefulness and pharmacokinetics of subcutaneous calcitriol in the treatment of secondary hyperparathyroidism

Nephrology Dialysis Transplantation

Volumn 11, Issue SUPPL. 3, 1996, Pages 54-57

  Torregrosa, J V ^a,b   Campistol, J M ^a   Mas M ^a   Montesinos, M ^a   Martinez De Osaba, M J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029757286     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/11.supp3.54     Document Type: Conference Paper

References (28)

1. Delmez JA, Slatopolsky E. Recent advances in the pathogenesis and therapy of uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1991; 72: 735-739
2. 3 of transcription of the pre-pro-parathyroid hormone gene. Endocrinology 1986; 119; 2864-2866
3. Silver J, Naveh-Many T, Mayer H et al. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 1986; 78: 1296-1301
4. Coburn JW, Llach F. Renal osteodystrophy and maintenance dialysis. In: Drucker W, Parsons FM, Maher JF, eds. Replacement of Renal Function by Dialysis, Dordrecht, Martinus Nijhoff, 1990: 697
5. Galceran T, Martin K, Morrissey JJ, Slatopolsky E. Role of 1,25-dihydroxyvitamin D on the skeletal resistance to parathyroid hormone. Kidney Int 1987; 32: 801-807
6. Hsu CH, Patel SR, Young EW et al. The biological action of calcitriol in renal failure. Kidney Int 1994; 46: 605-612
7. 3. J Clin Invest 1989; 83: 1349-1355
8. Mason R, Lissner D, Posen S, Norman AW. Blood concentrations of dihydroxylated vitamin D metabolites after an oral dose. Br Med J 1980; 449-450
9. Coburn JW. Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy. Kidney Int 1990; 38: S54-S61
10. Andres DL, Norris KC, Coburn JW et al. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989; 321: 274-279
11. Slatopolsky E, Weerts C, Thielan J et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-2143
12. Bover J, Rodriguez M, Trinidad P et al. Factors in the development of secondary hyperparathyroidism during graded renal failure in the rat. Kidney Int 1994; 45: 953-961
13. Julian BA, Quarles LD, Niemann KMW. Musculoskeletal complications after renal transplantation: Pathogenesis and treatment. Am J Kidney Dis 1992; 19: 99
14. Selgas R, Martinez ME, Miranda B et al. The pharmacokinetics of a single dose of calcitriol administered subcutaneously in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1993; 13: 122-125
15. Rolla D, Paoletti E, Marsano L et al. Effects of subcutaneous calcitriol administration on plasma calcium and parathyroid hormone concentrations in continuous ambulatory peritoneal dialysis uremic patients. Perit Dial Int 1993; 13: 118-121
16. Felsenfeld AJ, Llach F. Parathyroid gland function in chronic renal failure. Kidney Int 1993; 43: 771-789
17. St John A, Thomas MB, Davies CP et al. Determinants of intact parathyroid hormone and free 1,25-dihydroxyvitamin D levels in mild and moderate renal failure. Nephron 1992; 61: 422-427
18. 3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989; 35: 1049-1056
19. 2+ sensing receptor from bovine parathyroid. Nature 1993; 366: 575-580
20. Steiner RW, Ziegler M, Halasz NA et al. Effect of daily oral vitamin D and calcium therapy, hypophosphatemia, and endogenous 1,25-dihydroxycholecalciferol on parathyroid hormone and phosphate wasting in renal transplant recipients. Transplantation 1993; 56: 843-846
21. Torregrosa JV, Campistol JM, Montesinos M et al. Factors involved in the loss of bone mineral density after renal transplantation. Transplant Proc 1995; 27: 1946-1947
22. Rodriguez M, Felsenfeld AJ, Williams C, Pederson JA, Llach F. The effect of long term intravenous calcitriol administration on parathyroid function in hemodialysis patients. J Am Soc Nephrol 1991;2: 1014-1020
23. Fukagawa M, Okazaki R, Takanu K et al. Regression of parathyroid hyperplasia by calcitriol pulse therapy in patients on long-term dialysis. N Engl J Med 1990; 323: 421
24. Seidel A, Herrmann P, Klaus G et al. Kinetics of serum 1,84 iPTH after high dose of calcitriol in uremic patients. Clin Nephrol 1993; 39: 210-213
25. Delmez JA, Dougan CS, Gearing BK et al. The effects of intraperitoneal calcitriol on calcium and parathyroid hormone. Kidney Int 1987; 31: 795-799
26. Mai ML, Emmett M. Shiekh MS et al. Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 1989; 36: 690-695
27. Van der Merwe MH, Rodger RS, Grant AC et al. Low calcium dialysate and high dose oral calcitriol in the treatment of secondary hyperparathyroidism in hemodialysis patients. Nephrol Dial Transplant 1990; 5: 874-877
28. Dunlay R, Rodriguez M, Felsenfeld AJ, Llach F. Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. Kidney Int 1989; 36: 1093-1098